Poster Listing – Saturday 31 October 2026
| Theme | Poster no | Presenter name | Poster title | Poster Area | Gallery |
|---|---|---|---|---|---|
| Allied health: nursing | 1 | Yin Shuen Cheung | Initial patient experience with a telehealth service for rheumatology patients in a local hospital | 1 | A |
| Allied health: nursing | 2 | Joe Yee Fun | Patient Satisfaction with Nurse-Led Model of Care for Management of Gouty Arthritis. | 1 | A |
| Allied health: nursing | 3 | Mie Fusama | The Role of Nurses in Telephone Consultations for Patients with Rheumatoid Arthritis: A Qualitative Study | 1 | A |
| Allied health: nursing | 4 | Hoi Yin Ma | Telehealth in Rheumatology Nursing: Identifying Patient Barriers to Engagement | 1 | A |
| Allied health: nursing | 5 | Rona Cahyantari Merduaty | Exploring the ecological determinants of Systemic Lupus Erythematosus in a changing climate: A scoping review | 1 | A |
| Allied health: nursing | 6 | Orathai Wantha | The rate of hospitalization from viral pneumonia in systemic sclerosis patients after the influenza vaccination campaign | 1 | A |
| Antiphospholipid syndrome | 7 | Yuyang Zhang | Machine Learning-Based Risk Stratification for Predicting the Recurrence Risk of Thrombosis in Patients With Antiphospholipid Syndrome | 1 | A |
| Antiphospholipid syndrome | 8 | Yuyang Zhang | Machine Learning-Based Risk Stratification for Recurrence in Patients With Antiphospholipid Syndrome | 1 | A |
| Basic science related to rheumatic diseases | 9 | Saori Abe | Differential Expression of Activation Markers on dsDNA-reactive B cells Between Healthy Individuals and SLE Patients Points to Extrafollicular Activation | 1 | A |
| Basic science related to rheumatic diseases | 10 | Lina An | NFAT5-mediated lipid metabolic reprogramming confers ferroptosis resistance in RA-FLS | 1 | A |
| Basic science related to rheumatic diseases | 11 | Seo Yoon Ban | Allograft inflammatory factor-1 regulates inflammatory monocyte states and Th17 polarization in spondyloarthritis | 1 | A |
| Basic science related to rheumatic diseases | 12 | Gulshat Dalibayeva | Brucellosis as a Cause of Apparent Refractoriness of Rheumatoid Arthritis: A Diagnostic Challenge in Endemic Regions | 1 | A |
| Basic science related to rheumatic diseases | 13 | Ran Fan | Metagenomic Characterization of Gut Microbiota in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Taxonomic Shifts and Clinical Correlations | 1 | A |
| Basic science related to rheumatic diseases | 14 | Xiao Han | Novel Insights into B-cell Subsets Heterogeneity and BCR Clonality Features in Preclinical Systemic Lupus Erythematosus | 1 | A |
| Basic science related to rheumatic diseases | 15 | Kasturi Hazarika | Investigating 14-3-3 Eta Protein on Rheumatoid Arthritis: A cross sectional study on its diagnostic potential | 1 | A |
| Basic science related to rheumatic diseases | 16 | Rifanza Hirzan | In Silico Analysis Identifies ITGAM G649R as a Structurally Deleterious Variant in SLE | 1 | A |
| Basic science related to rheumatic diseases | 17 | Huiju Lee | Epigenetic Landscape of Osteoprogenitors in Ankylosing Spondylitis: FOXF2 Methylation as a Key Determinant of Pathological Bone Formation | 1 | A |
| Basic science related to rheumatic diseases | 18 | Yoshiro Kanayama | Transcriptomic Profiling of SLE Stratified by IRF5 Activation | 1 | A |
| Basic science related to rheumatic diseases | 19 | Nicholas Khoo | Multi-parametric Profiling of Adult Systemic Lupus Erythematosus Reveals Increased BAFF-Expressing CD45RA+ CD8+ T cells and CD8+ Immune Activation | 1 | A |
| Basic science related to rheumatic diseases | 20 | Shiho Kinoshita | An Approach to Identifying Inflammatory Osteoclast Precursors by Integrating In Vitro Culture Transcriptomics with Human Synovial scRNA-seq Data | 1 | A |
| Basic science related to rheumatic diseases | 21 | Michihiro Kono | From orphan TCRs to defined antigens: Development and validation of a T-Scan platform for disease-associated T cell receptor antigen discovery | 1 | A |
| Basic science related to rheumatic diseases | 22 | Oh Chan Kwon | Residual activated Th17 cells during inactive disease or low disease activity are associated with subsequent disease worsening in r-axSpA | 1 | A |
| Basic science related to rheumatic diseases | 23 | Seung Hoon Lee | Osteoclast-derived DEL1 promotes pathological bone formation of ankylosing spondylitis via regulating RUNX2 expression in osteoblasts | 1 | A |
| Basic science related to rheumatic diseases | 24 | Yan Li | Mechanism of Connexin 43 Involvement in the Pathogenesis of Rheumatoid Arthritis | 1 | A |
| Basic science related to rheumatic diseases | 25 | Olga Lomakina | Cell-type-specific colocalization of juvenile idiopathic arthritis GWAS signals with CD4 T-cell eQTLs reveals Treg-enriched regulatory architecture and implicates IL6ST | 1 | A |
| Basic science related to rheumatic diseases | 26 | Lamiaa Yaser Helmy Mohamed | Subclinical Immune Dysregulation in MEFV p.E148Q Revealed by Functional and Single-Cell Analyses | 1 | A |
| Basic science related to rheumatic diseases | 27 | Michio Mugitani | Expansion of a Novel Pre-Plasmablast Age-Associated B-Cell Subset in Rheumatoid Arthritis | 1 | A |
| Basic science related to rheumatic diseases | 28 | Shamaila Mumtaz | Awareness regarding drug teratogenecity and contraception and mode of contraception used by patients with rheumatological diseases | 1 | A |
| Basic science related to rheumatic diseases | 29 | Sotaro Nakajima | HLA-B27-negative axial spondyloarthritis exhibits clonal expansion of cytotoxic CD4 T cells. | 1 | A |
| Basic science related to rheumatic diseases | 30 | Kim Anh Nguyen | Evaluation of low-molecular-weight collagen injection in the treatment of lateral epicondylitis | 1 | A |
| Basic science related to rheumatic diseases | 31 | Jinyi Qian | A Single-Cell Atlas of Skin Endothelial Cells Reveals Shared and Disease-Specific Programs in Autoimmune Diseases | 1 | A |
| Basic science related to rheumatic diseases | 32 | Fajar Raharjo | Comparative Effects of Phaseolus vulgaris L. Extract, Plerixafor, and Methotrexate on Joint Damage in a Rat Model of Rheumatoid Arthritis | 1 | A |
| Basic science related to rheumatic diseases | 33 | Naga Tejaswini Ramineni | SDHC variants in an Indian father-daughter duo with IgG4-related disease (IgG4-RD) & Rosai Dorfman disease (RDD), respectively | 1 | A |
| Basic science related to rheumatic diseases | 34 | SOJIT TOMO | Concerted effect of Sphingosine Kinases and Sphingosine Lyase modulates Sphingosine-1-phosphate in patients with Rheumatoid Arthritis | 1 | A |
| Basic science related to rheumatic diseases | 35 | Haruka Tsuchiya | A senescent iCAF-like fibroblast state governs therapy resistance in rheumatoid arthritis | 1 | A |
| Basic science related to rheumatic diseases | 36 | Cesarius Singgih Wahono | Comparative Effects of Phaseolus vulgaris L. Extract, Plerixafor, and Methotrexate on Serum TNF-α Levels in Rat Model of Rheumatoid Arthritis | 1 | A |
| Basic science related to rheumatic diseases | 37 | Ni Wang | Exploring the role of RIPK4 in regulatory T cell-mediated inflammatory responses | 1 | A |
| Basic science related to rheumatic diseases | 38 | Sung Eun Wang | NSD1, H3K36me1/2 methyltransferase as a potential therapeutic target in Th17 cell-mediated autoinflammatory disease | 1 | A |
| Basic science related to rheumatic diseases | 39 | Yan Wang | Immune-inflammatory changes linked with organ damage of systemic lupus erythematosus | 1 | A |
| Basic science related to rheumatic diseases | 40 | Xiaoquan Wei | Interferon α-Induced HERC6 Provokes Podocyte Dysfunction via Mitotic Catastrophe in Lupus Nephritis | 1 | A |
| Basic science related to rheumatic diseases | 41 | Deng-ho Yang | Hispidin can inhibit active rheumatoid arthritis fibroblast like synoviocytes | 1 | A |
| Basic science related to rheumatic diseases | 42 | Neli Yovkova | Expression analysis of microribonucleic acids in serum and determination of their diagnostic and prognostic value in patients with psoriatic arthritis | 1 | A |
| Basic science related to rheumatic diseases | 43 | Jingtao Zhang | NR1A as a Molecular Switch of Inflammatory Cytokine Storm in Rheumatoid Arthritis | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 44 | Razan Al Yaarubi | Fever on unknown origin, hepatic granuloma and lymphadenopathy in Bechet’s disease: a diagnostic challenge in a tuberculosis endemic region. | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 45 | Chandhu Arumugham Sugandhilal | Treatment response and outcomes in idiopathic granulomatous mastitis: A retrospective single centre observational study | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 46 | Joban Deol | Intracranial Aneurysms Preceding Mucocutaneous Features in Behcet's Disease: A diagnostic and Therapeutic Challenge | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 47 | Keyur Desai | TNF inhibitors in refractory Vogt-Koyanagi-Harada (VKH) syndrome: Experience from a tertiary centre | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 48 | Mehmet Tuncay Duruoz | Validity and Psychometric Properties of the Duruöz Hand Index (DHI) in Patients with Behçet’s Disease: A Preliminary Study | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 49 | Juan Raphael Gonzales | Ocular Syphilis and Tuberculosis in a Patient With Mixed Connective Tissue Disease: A Case Report | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 50 | Jison Hong | Validation of the MASTitis Score: A Novel Triage Tool for Early Transition to Immunosuppressive Therapy for Idiopathic Granulomatous Mastitis | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 51 | Elena Joerns | Features of short telomere syndrome are common in interstitial pneumonia with autoimmune features and affect outcomes | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 52 | Moonju Kim | Increased Frequency and Infiltration of Cytotoxic CD4⁺ T Cells in Patients with Ankylosing Spondylitis and a Curdlan-Induced Arthritis Mouse Model | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 53 | Claryssa Gabrielle Ligon | Beyond Imaging: Persistent Mononeuritis in Neuro-Behçet’s Disease Despite Radiologic Response to Pulse Corticosteroid Therapy | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 54 | Sean Lim | Immunological Heterogeneity in Ocular and Systemic Sarcoidosis: Insights from Biopsy-Proven Disease | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 55 | Galina Lukina | Efficacy and Safety of Olokizumab in Patients with Polymyalgia Rheumatica: Results from the Phase 3 PROMISE Study | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 56 | Ayaka Maeda | Interleukin-6 Blockade for Refractory Neuro-Behçet’s Disease: A Systematic Literature Review | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 57 | Dikshaladevi Nisanthan | A silent storm: Isolated pulmonary hypertension as the first clue to mixed connective tissue disease | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 58 | Pavel Novikov | Direct IL-6 inhibition with olokizumab in polymyalgia rheumatica: a multicenter case series | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 59 | KAMKA OMAROVA | Diagnostic Uncertainty: A Patient with Features of Behçet’s Disease Outside ICBD Criteria | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 60 | Tatiana Reshetnyak | Serum NETosis markers in Behçet's disease | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 61 | Manan Shah | A case of Behçet-like disease with prominent intestinal features and Trisomy-8 associated Myelodysplastic syndrome successfully treated with Infliximab | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 62 | Owen Tungol | Intestinal Behçet’s Disease Presenting with Recurrent Ileocecal Mass | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 63 | Wenyu Xu | Clinical heterogeneity and sex-stratified characteristics in relapsing polychondritis | 1 | A |
| Behcet’s disease and miscellaneous rheumatic conditions | 64 | Jun Zou | Intestinal Ultrasound in Intestinal Behçet's Disease: A Comprehensive Tool for Diagnosis, Activity Assessment, and Prognosis | 1 | A |
| Case reports | 65 | Hannisha Patrice Alfonso | A case of multiple autoimmune syndromes in a Filipino female | 1 | A |
| Case reports | 66 | Mengxue Tian | Good efficacy achieved by telitacicept, corticosteroids, and immunosuppressants in the treatment of SLE combined with MOG-AD. | 1 | A |
| Clinical immunology related to rheumatic diseases | 67 | Yuyang Zhang | Metabolomics Reveals Metabolic Markers for Individuals in Rheumatoid Arthritis Associated Interstitial Lung Disease | 1 | A |
| Crystal-induced diseases | 68 | Noor Deanna binti Abdul Raof | When Gout Breaks the Surface: A Rare Case of Disseminated Cutaneous Tophus Ulceration | 1 | A |
| Crystal-induced diseases | 69 | Hajar Al Majarfi | A rare case of gout arthritis secondary to D-lactate dehydrogenase enzyme deficiency: Case report and literature review | 1 | A |
| Crystal-induced diseases | 70 | Iuliia Bairakova | Gouty spondylitis: a mimic of axial spondyloarthritis? Analysis of 183 cases | 1 | A |
| Crystal-induced diseases | 71 | Iuliia Bairakova | Successful treatment of morphologically and DECT‑confirmed gouty spondylitis | 1 | A |
| Crystal-induced diseases | 72 | Queency Joy Batucan | Fatal multi-organ failure and rare cardiotoxicity following acute colchicine overdose: A case report | 1 | A |
| Crystal-induced diseases | 73 | Zhihan Chen | Dyslipidemia and Gout Risk: Insights from Large Cohorts with CVD Stratification | 1 | A |
| Crystal-induced diseases | 74 | Praveena Chiowchanwisawakit | Underutilization of serum uric acid testing in urolithiasis: Prevalence, associated factors, and hyperuricemia in a Thai tertiary care center | 1 | A |
| Crystal-induced diseases | 75 | Bhavisha Desai | Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study | 1 | A |
| Crystal-induced diseases | 76 | Princess Joy Estrella | Crystal-Negative Polyarticular Flare in Advanced Tophaceous Gout: A Diagnostic Pitfall — A Case Report | 1 | A |
| Crystal-induced diseases | 77 | Joe Yee Fun | Nurse-Led Care Achieves Comparable Outcomes in Gout Management: A 1-Year Study. | 1 | A |
| Crystal-induced diseases | 78 | Rose Elaine Gumafelix | Consistent Serum Uric Acid Reduction With Dapagliflozin: A Systematic Review and Meta-Analysis | 1 | A |
| Crystal-induced diseases | 79 | Mooi Khin H'ng | Clinical Characteristics and Treatment Outcome of Gout Patients in a Single Tertiary Rheumatology Center in Penang, Malaysia | 1 | A |
| Crystal-induced diseases | 80 | Wooseong Jeong | Dual-Energy CT in Gout: Associations With Management and Outcomes | 1 | A |
| Crystal-induced diseases | 81 | Yoon Kam Hon | Mixed crystal deposition disease a case series of 5 Chinese patients | 1 | A |
| Crystal-induced diseases | 82 | Wanruchada Katchamart | 2026 Thai Rheumatism Association Guideline for Management of Gout and Asymptomatic Hyperuricemia | 1 | A |
| Crystal-induced diseases | 83 | Robert Keenan | Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Uncontrolled Gout or Tophaceous Gout Patients in Asia-Pacific Patients | 1 | A |
| Crystal-induced diseases | 84 | Robert Keenan | Supratherapeutic Doses of Pozdeutinurad: Pharmacokinetic and Pharmacodynamic Assessment in Healthy Subject Volunteers | 1 | A |
| Crystal-induced diseases | 85 | Zumrad Khamroeva | Gender Differences in Clinical and Biochemical Features of Gout: A Comparative Study | 1 | A |
| Crystal-induced diseases | 86 | Min Jung Kim | Temperature Variability and the Risk of Gout Flares: A Time-Stratified Case-Crossover Study | 1 | A |
| Crystal-induced diseases | 87 | Pornsawan Leosuthamas | Factors Influencing Successful Serum Uric Acid Control in Patients with Gout | 1 | A |
| Crystal-induced diseases | 88 | Danagul Maksot | Demographic profile, comorbidities, and predictors of tophaceous gout: first results from the Kazakhstan Gout Registry within APLAR | 1 | A |
| Crystal-induced diseases | 89 | Masashi Momose | Milwaukee Shoulder Syndrome-like Destructive Gouty Arthritis and Spinal Gout: A Case Report of Japanese female | 1 | A |
| Crystal-induced diseases | 90 | Kanika Nair | Real-World Allopurinol Adherence After Hospitalisation for Gout: Insights from a Retrospective Australian Cohort | 1 | A |
| Crystal-induced diseases | 91 | Thi Thuy An Nguyen | Clinical and Dietary Factors Associated With Acute Gout Severity: A Pilot Study in Haiphong, Vietnam | 1 | A |
| Crystal-induced diseases | 92 | Nazgul Omurzakova | Gout and Hyperuricemia in the Kyrgyz Republic | 1 | A |
| Crystal-induced diseases | 93 | Ki-Jeong Park | Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout | 1 | A |
| Crystal-induced diseases | 94 | Nghia Pham | Clinical Epidemiology of Gout in Vietnam: A Scoping Review Identifying Evidence Gaps in the Context of Regional Registry Initiatives (2015–2026) | 1 | A |
| Crystal-induced diseases | 95 | Tatiana Popkova | Association and clinical features in patients with calcium pyrophosphate crystal deposition disease and the presence/absence of hyperuricemia (preliminary data) | 1 | A |
| Crystal-induced diseases | 96 | Tatiana Popkova | Comparative characteristics of anamnestic and laboratory parameters in patients with different phenotypes of hyperuricemia (preliminary data) | 1 | B |
| Crystal-induced diseases | 97 | Tatiana Popkova | Evaluation of the efficacy of febuxostat therapy in patients with gout and normal and reduced renal function | 1 | B |
| Crystal-induced diseases | 98 | Tatiana Popkova | Ultrasound signs of monosodium urate crystal deposition in the renal parenchyma in patients with gout (preliminary data) | 1 | B |
| Crystal-induced diseases | 99 | John Lee Salvador | Impact of Gout on Health-Related Quality of Life Among Filipino Patients Using the Gout Impact Scale: A Cross-Sectional Study | 1 | B |
| Crystal-induced diseases | 100 | Nayantara Shenoy | Sex Differences in Comorbidity Profiles and Polyarticular Involvement in Gout: A Multivariate Analysis | 1 | B |
| Crystal-induced diseases | 101 | Kichul Shin | Metabolic inflammation over urate-lowering therapy: treat-to-target is not enough | 1 | B |
| Crystal-induced diseases | 102 | Nattawat Watcharajittanont | Gout Flares are More Likely to Develop on Paretic Limbs in Patients with Acute Stroke: a 10-year Retrospective Cohort Study | 1 | B |
| Crystal-induced diseases | 103 | Fariz Yahya | Prevalence and Predictors of Gout in Psoriatic Disease: A 10-Year Retrospective Cohort Study in a Rheumatology Tertiary Centre | 1 | B |
| Crystal-induced diseases | 104 | Hui Yang | Effects of Urate Lowering Therapy (ULT) in Gout with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Systematic Review | 1 | B |
| Genetics | 105 | Jude Philip Cebrecus | From Flare to Failure – Systemic Lupus Erythematosus Complicated by Myelodysplastic Syndrome with del(7q31): A Case Report | 1 | B |
| IgG4 - related disease | 106 | Anna Maria | Frequency of Non-Hodgkin Lymphoma Diagnoses and All-Cause Mortality in IgG4-Related Disease Versus Sjögren Disease: A Retrospective Cohort Study | 1 | B |
| Infection-related rheumatic diseases | 107 | Mitzell Ariane Arenal | When crystals mislead: unmasking tuberculous arthritis on a crystal-proven gout patient with polycythemia vera on ruxolitinib | 1 | B |
| Infection-related rheumatic diseases | 108 | Sunith Himantha Atukorale | Predictive Modeling of Chronic Chikungunya Arthritis: Epidemiological and Clinical Correlates in a Sri Lankan Cohort | 1 | B |
| Infection-related rheumatic diseases | 109 | Assadullah Dahani | Infection Burden in Rheumatological Patients Receiving Biologic Therapy | 1 | B |
| Infection-related rheumatic diseases | 110 | My Doan Ai Thao | Hepatitis B–Associated Cryoglobulinemic Vasculitis Presenting as Membranoproliferative Glomerulonephritis Mimicking Lupus Nephritis: A Diagnostic Challenge | 1 | B |
| Infection-related rheumatic diseases | 111 | Sevanth K Gowda | Unilateral sacroilitis in the elderly: when infection masquerades as spondyloarthritis | 1 | B |
| Infection-related rheumatic diseases | 112 | Allerma Herdiman | The Role of NLR and PLR as Screening Tools for Bacterial Infection in Patients with SLE Flare | 1 | B |
| Infection-related rheumatic diseases | 113 | Siripat Kaewnamchai | Effectiveness of latent tuberculosis screening prior to initiation of targeted therapies in patients with autoimmune inflammatory rheumatic disease and vasculitides. | 1 | B |
| Infection-related rheumatic diseases | 114 | Anastasiia Kebina | Life-threatening hemophagocytic syndrome mimicking Still's disease secondary to meningococcemia: successfully treated with cyclosporine A and glucocorticoids | 1 | B |
| Infection-related rheumatic diseases | 115 | Yu Han Koh | An Elusive Diagnosis: Rapidly Destructive Culture-Negative Gonococcal Shoulder Arthritis Diagnosed by Synovial Fluid PCR. | 1 | B |
| Infection-related rheumatic diseases | 117 | Mary Grace Matias Gumpic | Tuberculosis Among Patients With Systemic Lupus Erythematosus in a Tertiary Hospital in the Philippines | 1 | B |
| Infection-related rheumatic diseases | 118 | Gerrhal Gean Pineda | Beyond the fistula: a rare journey of burkholderia cepacia complex to the knee | 1 | B |
| Infection-related rheumatic diseases | 119 | Rani Pujarwad | Unmasking Right-Sided Endocarditis in Culture-Negative Sacroiliitis: A Diagnostic Conundrum in a Tuberculosis-Endemic Region. | 1 | B |
| Infection-related rheumatic diseases | 120 | Rizki Febriani Putri | Persistent Pain in Chronic Tophaceous Gout Revealing Superimposed Tuberculous Arthritis in a Tuberculosis-Endemic Setting | 1 | B |
| Infection-related rheumatic diseases | 121 | Sushant Shinde | Iguratimod in post-viral arthritis refractory to methotrexate: a case series | 1 | B |
| Infection-related rheumatic diseases | 122 | Toshitaka Yukishima | Association between standardized plasma cytomegalovirus DNA levels and pp65 antigenemia in patients with rheumatic diseases | 1 | B |
| Medical technologies and innovation (including AI) | 123 | Fahd Adeeb | Cautious Optimism: A Pilot Study of Patient Perceptions of Artificial Intelligence in Rheumatology Care in Malaysia | 1 | B |
| Medical technologies and innovation (including AI) | 124 | Mustafa Alhayali | Attitudes and Perceptions Toward Artificial Intelligence Among Practicing Rheumatologists in Iraq: A Cross-Sectional Web-Based Survey | 1 | B |
| Medical technologies and innovation (including AI) | 125 | Muhammad Izzul Islam Bin Faisal | Machine Learning Model in Predicting Remission and Kidney Damage in Proliferative Lupus Nephritis Patients in Universiti Kebangsaan Malaysia | 1 | B |
| Medical technologies and innovation (including AI) | 126 | Byeongzu Ghang | Bridging Pharmacogenomic Knowledge and Clinical Practice: CPIC-Guided Decision Support Through EMR-Independent Integration and Patient Genomic Data | 1 | B |
| Medical technologies and innovation (including AI) | 127 | Gerber Gomez | Analytical evaluation of a fully-automated multiplex microarray-immunoassay for detecting fifteen autoimmune rheumatic disease autoantibodies in a clinical laboratory in Kuwait | 1 | B |
| Medical technologies and innovation (including AI) | 128 | Dan Guo | Between Enthusiasm and Vigilance: AI Adoption, Attitudes, and Verification Behaviors Among Clinical Interns | 1 | B |
| Medical technologies and innovation (including AI) | 129 | Ayush Jain | Artificial Intelligence in Rheumatology: A Narrative Review of Current Applications and Barriers to Clinical Adoption in the Asia-Pacific Region | 1 | B |
| Medical technologies and innovation (including AI) | 130 | Jinyung Ju | Uncovering Hidden Clinical Endotypes in Systemic Sclerosis: A Multi-System Machine Learning Phenomapping and Risk Prediction Approach | 1 | B |
| Medical technologies and innovation (including AI) | 131 | Chung Mao Kao | 2026 Taiwan College of Rheumatology Consensus-Based Recommendations for CAR-T Cell Therapy for Autoimmune Rheumatic Diseases | 1 | B |
| Medical technologies and innovation (including AI) | 132 | Yu Heng Kwan | Consolidated Framework for Implementation Research (CFIR) identification of facilitators and barriers to remote monitoring care model for stable axial spondyloarthritis | 1 | B |
| Medical technologies and innovation (including AI) | 133 | Yu Heng Kwan | Development and validation of an Automated Monitoring System for stable patients with axial spondyloarthritis | 1 | B |
| Medical technologies and innovation (including AI) | 134 | Yu Heng Kwan | Machine learning models in predicting flares in patients with rheumatoid arthritis: A systematic review and meta-analysis. | 1 | B |
| Medical technologies and innovation (including AI) | 135 | Yan Kitty Kwok | ANailyzer : An Automated Capillary Detection and Classification Software for Nailfold Capillaroscopy | 1 | B |
| Medical technologies and innovation (including AI) | 136 | Somin Lee | AI-Based Nailfold Capillaroscopy for EULAR-Standardized Classification and Identification of Reversible Microvascular Patterns in Idiopathic Inflammatory Myopathies | 1 | B |
| Medical technologies and innovation (including AI) | 137 | Pui Ying Leong | Transforming Rheumatology Care: Real-World Mobile Health Implementation Improves Engagement and Continuity | 1 | B |
| Medical technologies and innovation (including AI) | 138 | Crissa Mae Manalastas | The New Teammate: Assistive AI Tools In Rheumatology Practice | 1 | B |
| Medical technologies and innovation (including AI) | 139 | Kiwon Moon | A Data Augmentation–Based Prediction Model for Target Serum Urate Achievement in Patients with Gout | 1 | B |
| Medical technologies and innovation (including AI) | 140 | Nghia Pham | A simple low-cost approach to polarized microscopy for synovial crystal detection | 1 | B |
| Medical technologies and innovation (including AI) | 141 | Indrayana Sunarso | Less is More: Clinical-Only Machine Learning Rivals Multimodal Multi-Omics in Predicting Rheumatoid Arthritis Remission | 1 | B |
| Medical technologies and innovation (including AI) | 142 | York Kiat Tan | Thermography as a scalable alternative to power Doppler ultrasound in predicting rheumatoid arthritis relapse: a longitudinal proof-of-concept study | 1 | B |
| Medical technologies and innovation (including AI) | 143 | Tulus Widiyanto | Data-Driven Screening for Infection Risk in Hospitalized SLE: A Dual-Model Machine Learning Approach | 1 | B |
| Medical technologies and innovation (including AI) | 144 | Tulus Widiyanto | Multimodal Artificial Intelligence for Clinical and Radiologic Severity Assessment in CTD-ILD | 1 | B |
| Medical technologies and innovation (including AI) | 145 | Chuanhui Xu | Large language model use and training needs among rheumatologists: An APLAR Young Rheumatologists international survey | 1 | B |
| Medical technologies and innovation (including AI) | 146 | Cansu Yazar | Enhancing Personalized Care for Rheumatology Patients with Artificial Intelligence | 1 | B |
| Osteoarthritis | 147 | Hannisha Patrice Alfonso | Osteoarthritis content and user engagement on Facebook: an analysis of public videos and reels | 1 | B |
| Paediatric rheumatology | 148 | Taha Akhtar | Tuberculosis as a mimicker for chronic synovitis and tenosynovitis in Enthesitis Related Arthritis | 1 | B |
| Paediatric rheumatology | 149 | Yuko Akutsu | Early risk stratification of macrophage activation syndrome in systemic juvenile idiopathic arthritis: a nationwide registry-based study | 1 | B |
| Paediatric rheumatology | 150 | Ekaterina I. Alekseeva | High-Sensitivity CRP Predicts Disease Flare After TNF Inhibitor Discontinuation in Non-Systemic Juvenile Idiopathic Arthritis | 1 | B |
| Paediatric rheumatology | 151 | Ekaterina I. Alekseeva | The efficacy and safety of the JAK-kinase inhibitor Upadacitinib in children with rheumatic diseases. | 1 | B |
| Paediatric rheumatology | 152 | Ekaterina I. Alekseeva | Use of Tofacitinib in children with rheumatic diseases: A Single-Center Study of Long-Term Efficacy and Safety | 1 | B |
| Paediatric rheumatology | 153 | Fatimah Alkhars | Correlation Between MRI And Bone Biopsy In Pediatric CNO | 1 | B |
| Paediatric rheumatology | 154 | Noora Almajed | Vaccination practices and barriers in pediatric rheumatology: Insights from the MENA and Asia-Pacific regions | 1 | B |
| Paediatric rheumatology | 155 | Rana Almukhlifi | Spectrum of Lung Involvement in Systemic onset Juvenile Idiopathic Arthritis: A Multicenter Cohort Study | 1 | B |
| Paediatric rheumatology | 156 | Ozge Altug Gucenmez | Association of systemic inflammatory indices with renal and gastrointestinal involvement in childhood iga vasculitis | 1 | B |
| Paediatric rheumatology | 157 | Diadra Annisa | When Skin Tightens and Organs Follow: A Case Series of Juvenile Systemic Sclerosis from Jakarta | 1 | B |
| Paediatric rheumatology | 158 | Ka-Nam Au | Asymptomatic Paediatric Primary Sjögren’s Syndrome with persistent hypergammaglobulinemia and high ESR diagnosed with PET-CT and Schirmer test: A case report | 1 | B |
| Paediatric rheumatology | 159 | Narendra Bagri | Clinical Correlates Of Interstitial Lung Disease Patterns In Juvenile Dermatomyositis: A Single-Center Cohort from India | 1 | B |
| Paediatric rheumatology | 160 | Narendra Bagri | Tofacitinib for calcinosis cutis associated with juvenile dermatomyositis: An open-label single-arm study (TOFCAL Study) | 1 | B |
| Paediatric rheumatology | 161 | Reima Bakry | Toward a combined pediatric Ophthalmology- Rhuematology clinic: Patient Characteristics, Diagnoses, and Management in One- year experience | 1 | B |
| Paediatric rheumatology | 162 | Lilija Bancevica | Retrospective Characterization of Juvenile Dermatomyositis in Latvia: Clinical, Radiologic, Laboratory Findings and Therapeutic Approaches from 2010 to 2025 | 1 | B |
| Paediatric rheumatology | 163 | Hannah Bazer | Polyarteritis Nodosa Associated with Wiskott-Aldrich Syndrome in a Filipino Child: A Case Report | 1 | B |
| Paediatric rheumatology | 164 | Mary Jane Carbonell | Diagnostic Challenge in Pediatric Rheumatology: Multifocal Septic Arthritis From Disseminated Staphylococcus aureus | 1 | B |
| Paediatric rheumatology | 165 | Mary Jane Carbonell | Triple Threat: Nephritis, PRES, and Acute Limb Ischemia in a Pediatric Lupus Patient | 1 | B |
| Paediatric rheumatology | 166 | Oi Man Chan | Refractory Peripheral Ulcerative Keratitis and Corneal Perforation Complicating Paediatric ANCA-Associated Vasculitis | 1 | B |
| Paediatric rheumatology | 167 | Aniqa Chaudhary | Comparison of various predictive factors among methotrexate responders and non-responders in children with juvenile idiopathic arthritis (jia) | 1 | B |
| Paediatric rheumatology | 168 | Wan U Cheong | Integrative Bulk and Single-Cell Transcriptomics reveal Interferon-stimulated Disease Stage-specific T Cells Primed for Chronic Inflammation in Paediatric Lupus Nephritis | 1 | B |
| Paediatric rheumatology | 169 | Leolen Cordova | Predictive Factors and Development of Risk Scoring System for Coronary Artery Lesions in Kawasaki Disease: A Single-Center Retrospective Cohort Study | 1 | B |
| Paediatric rheumatology | 170 | Leolen Cordova | Predictive Factors and Risk Scoring System for Coronary Artery Lesions in Kawasaki Disease: A Single-Center Retrospective Cohort Study | 1 | B |
| Paediatric rheumatology | 171 | Abhishikta Dey | Sexual health and contraception in paediatric rheumatology: a national Australian workforce survey | 1 | B |
| Paediatric rheumatology | 172 | Ivan Foeldvari | Clinical characteristics associated with progressive interstitial lung disease in juvenile systemic sclerosis: 12-month data from the Juvenile Scleroderma Inception Cohort | 1 | B |
| Paediatric rheumatology | 173 | Ivan Foeldvari | Clinical characteristics associated with progressive skin involvement in juvenile systemic sclerosis: 12-month data from the Juvenile Scleroderma Inception Cohort | 1 | B |
| Paediatric rheumatology | 174 | Ivan Foeldvari | Distinct Organ Involvement and Outcome Profiles in Diffuse versus Limited Juvenile Systemic Sclerosis: Results from the Juvenile Systemic Scleroderma InceptionCohort | 1 | B |
| Paediatric rheumatology | 175 | Ivan Foeldvari | Gender differences in clinical patterns in juvenile systemic sclerosis: updates from the Juvenile Scleroderma Inception Cohort | 1 | B |
| Paediatric rheumatology | 176 | Ivan Foeldvari | Juvenile systemic sclerosis with dermatomyositis-like overlap features represents a distinct clinical phenotype: updates from the Juvenile Scleroderma Inception Cohort | 1 | B |
| Paediatric rheumatology | 177 | Ivan Foeldvari | Organ involvement patterns by anti Scl70 and anti-centromere status in juvenile systemic sclerosis. Results of the juvenile scleroderma inception cohort. | 1 | B |
| Paediatric rheumatology | 178 | Ivan Foeldvari | Presence of Nailfold Capillary Abnormalities Is Associated with More Severe Organ Involvement in Juvenile Systemic Sclerosis: Results from the JuvenileSystemicSclerodermaInceptionCohort | 1 | B |
| Paediatric rheumatology | 179 | Sabin George | Baseline STIR MRI Fatty Infiltration Predicts Disease Chronicity and Remission Status in Juvenile Dermatomyositis | 1 | B |
| Paediatric rheumatology | 180 | Ria Ghosh | Clinical spectrum, coronary artery involvement and treatment of Kawasaki disease: experience from study in tertiary care centre in eastern India. | 1 | B |
| Paediatric rheumatology | 181 | Zainab Hilal | Early onset Juvenile Dermatomyositis: Phenotype Disparities and Novel Genetic Findings | 1 | B |
| Paediatric rheumatology | 182 | Assunta Chi Hang Ho | Treating Juvenile Idiopathic Arthritis to Target in Hong Kong: a proposed framework | 1 | B |
| Paediatric rheumatology | 183 | Junjie Huang | Predictors of temporomandibular joint arthritis in juvenile idiopathic arthritis | 1 | B |
| Paediatric rheumatology | 184 | Junjie Huang | Treatment and outcomes of temporomandibular joint arthritis in an Asian juvenile idiopathic arthritis cohort | 1 | B |
| Paediatric rheumatology | 185 | Mohammad Imnul Islam | Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in The Treatment of Refractory Polyarticular Juvenile Idiopathic Arthritis Patients | 1 | B |
| Paediatric rheumatology | 186 | Mohammad Imnul Islam | Serum Ferritin and Interleukin-6 as Markers of Renal Involvement in Pediatric Systemic Lupus Erythematosus: A Cross-Sectional Study | 1 | B |
| Paediatric rheumatology | 187 | Jiwon Jung | Patterns of kidney involvement after corticosteroid treatment for extrarenal symptoms in pediatric IgA vasculitis (Henoch–Schönlein Purpura): Phenotypes and outcomes | 1 | B |
| Paediatric rheumatology | 188 | Dina Kairatova | Successful Use of Adalimumab in a Refractory Juvenile Dermatomyositis with Severe Muscle Atrophy | 1 | B |
| Paediatric rheumatology | 189 | Mikhail Kostik | ANCA-Positive and ANCA-Negative Granulomatosis with Polyangiitis in Children: Different Pathways to Diagnosis | 1 | B |
| Paediatric rheumatology | 190 | Mikhail Kostik | Characteristics of Children with Kawasaki Disease: A Single Center Experience in Saint Petersburg, Russia | 1 | B |
| Paediatric rheumatology | 191 | Mikhail Kostik | Clinical predictors of temporomandibular joint damage in children with juvenile idiopathic arthritis | 1 | B |
| Paediatric rheumatology | 192 | Mikhail Kostik | Clinical profile of non-systemic juvenile idiopathic arthritis by age of onset | 1 | B |
| Paediatric rheumatology | 193 | Mikhail Kostik | Flare predictors in juvenile idiopathic arthritis after methotrexate discontinuation | 1 | B |
| Paediatric rheumatology | 194 | Mikhail Kostik | Patterns of Biological Disease-Modifying Anti-Rheumatic Drugs Switching in Patients with Juvenile Idiopathic Arthritis: A Single Center Experience | 1 | B |
| Paediatric rheumatology | 195 | Ivan Kriulin | Efficacy and safety of alprostadil in children with systemic connective tissue diseases and ischemic injury: results of retrospective cohort study | 1 | B |
| Paediatric rheumatology | 196 | Tatiana Kriulina | APPROACHES TO THE MANAGEMENT OF CHILDREN WITH RHEUMATIC DISEASES IN THE RUSSIA: RESULTS OF A NATIONAL SURVEY OF PEDIATRIC RHEUMATOLOGISTS | 1 | B |
| Paediatric rheumatology | 197 | Tatiana Kriulina | Efficacy and safety of anakinra in children with secondary hemophagocytic syndrome: a retrospective study | 1 | B |
| Paediatric rheumatology | 198 | Tatiana Kriulina | Efficacy and Safety of Tocilizumab Biosimilar for Systemic Juvenile Idiopathic Arthritis: Results of a Multicenter Study in Russia | 1 | B |
| Paediatric rheumatology | 199 | Tatiana Kriulina | Optimization of the emapalumab administration regimen for the treatment of macrophage activation syndrome in children: a single‑center experience | 1 | B |
| Paediatric rheumatology | 200 | Tatiana Kriulina | Outcomes of switching patients with systemic juvenile idiopathic arthritis to a Russian tocilizumab biosimilar: preliminary data from an observational study | 1 | B |
| Paediatric rheumatology | 201 | Saverio La Bella | Baseline Characteristics of the Prospective, Multicentre, International Cohort for the New Classification Criteria of Juvenile Idiopathic Arthritides | 1 | B |
| Paediatric rheumatology | 202 | Olga Lomakina | Organizing care for children with rheumatic diseases in a metropolitan area (Moscow) | 1 | B |
| Paediatric rheumatology | 203 | Danagul Maksot | Multiorgan Juvenile-Onset Systemic Lupus Erythematosus with Nephritis and Polyserositis: A Case of Diagnostic and Therapeutic Challenge | 1 | B |
| Paediatric rheumatology | 204 | Zaferulla Khan Mariyam Jezeema | Clinicodemographic Profile and Spectrum of Paediatric Rheumatological Diseases at Sri Lanka’s National Referral Centre: A Single-Centre Descriptive Study | 1 | B |
| Paediatric rheumatology | 205 | Anzhela Nargizyan | Сlinical and diagnostic profile of a child with chronic recurrent multifocal osteomyelitis | 1 | B |
| Paediatric rheumatology | 206 | Maria Carmen Neri Gallentes | Juvenile dermatomyositis successfully treated with rituximab: a case report | 1 | B |
| Paediatric rheumatology | 207 | Maria Carmen Neri Gallentes | Pharyngeal phase dysphagia in childhood systemic lupus erythematosus – a case report | 1 | B |
| Paediatric rheumatology | 208 | Irina Nikishina | Janus kinase inhibitors in juvenile idiopathic inflammatory myopathies: single center real-life data | 1 | B |
| Paediatric rheumatology | 209 | Irina Nikishina | Multitarget therapy with Tofacitinib and Palovarotene in Fibrodysplasia Ossificans Progressiva: a Russian real-world experience | 1 | B |
| Paediatric rheumatology | 210 | Irina Nikishina | Single center real-world data of the Golimumab therapy in patients with different Juvenile Idiopathic Arthritis subtypes | 1 | B |
| Paediatric rheumatology | 211 | Dikshaladevi Nisanthan | Blinded by the storm:interferonopathy presenting with an HLH like phenotype | 1 | B |
| Paediatric rheumatology | 212 | Jitendra Oswal | Clinical Profile and Outcomes of Autoimmune Uveitis in Children: A Case Series from India | 1 | B |
| Paediatric rheumatology | 213 | Akmaral Otegen | Clinical characteristics and management of pediatric fibrodysplasia ossificans progressiva: a single-center case series | 1 | B |
| Paediatric rheumatology | 214 | Akmaral Otegen | Clinical characteristics and outcomes of pediatric patients with rheumatic diseases treated with IL-1 inhibitors: a single-center experience | 1 | B |
| Paediatric rheumatology | 215 | Bansri Patel | A new chapter in Childhood Systemic Lupus Erythematosus: Real world experience with Belimumab from a rural cohort | 2 | C |
| Paediatric rheumatology | 216 | Vera Podzolkova | Age-related characteristics of pediatric Takayasu arteritis — insights from the first Russian multicenter cohort study | 2 | C |
| Paediatric rheumatology | 217 | Vera Podzolkova | Capillaroscopic and rheological features in juvenile systemic sclerosis vs juvenile dermatomyositis: a two-center study | 2 | C |
| Paediatric rheumatology | 218 | Gulsara Rakhym | Interplay between infection and autoinflammation: juvenile idiopathic arthritis in the setting of brucellosis | 2 | C |
| Paediatric rheumatology | 219 | Gulsara Rakhym | Observation of patients with blau and vogt-koyanagi-harada syndrome | 2 | C |
| Paediatric rheumatology | 220 | Regine Joyce Rostata | Kawasaki Disease Shock Syndrome in a Filipino Child: A Case Report | 2 | C |
| Paediatric rheumatology | 221 | Nayantara Shenoy | Tofacitinib in refractory calcinosis associated with juvenile dermatomyositis: a case series and review | 2 | C |
| Paediatric rheumatology | 222 | Masaki Shimizu | Clinical support handbook for health care transition in juvenile idiopathic arthritis and adolescent and young adult-onset rheumatoid arthritis | 2 | C |
| Paediatric rheumatology | 223 | Meghana Shridhar | Bisphosphonate therapy in paediatric CRMO: unprecedented real-world imaging outcomes from a large Asian cohort | 2 | C |
| Paediatric rheumatology | 224 | Anna Angela Talatala | Takayasu arteritis presenting as pediatric arterial ischemic stroke in an 8 year old Filipino female | 2 | C |
| Paediatric rheumatology | 225 | Poomrapee Tantikittipisut | Lupus Pneumonitis as an Initial Presentation of Childhood-onset Systemic Lupus Erythematosus: A Case Report and Literature Review | 2 | C |
| Paediatric rheumatology | 226 | Abdul Mahin Tazbir | Refractory ‘Juvenile Idiopathic Arthritis’ Unmasked as Progressive Pseudorheumatoid Dysplasia: Lessons from a 13-Year Delay | 2 | C |
| Paediatric rheumatology | 227 | Kai Liang Teh | Anti-Adalimumab Antibodies in Childhood Rheumatic Diseases and their predictors: Findings From a Real-World Asian Pediatric Cohort | 2 | C |
| Paediatric rheumatology | 228 | Kai Liang Teh | Clinical and immunologic characteristics of childhood onset systemic lupus erythematosus in the Asia Pacific: The CLASPER observation | 2 | C |
| Paediatric rheumatology | 229 | Kai Liang Teh | High Immunogenicity of Adalimumab in Childhood Rheumatic Diseases: Experience of an Asian Paediatric Cohort | 2 | C |
| Paediatric rheumatology | 230 | Kai Liang Teh | Time to Lupus Low Disease Activity State and Its Predictors in Childhood-Onset SLE: A Multi-National CLASPER Cohort Study | 2 | C |
| Paediatric rheumatology | 231 | Nadezhda Tsurikova | Withdrawal of monotherapy after achieving remission in juvenile idiopathic arthritis: a systematic review | 2 | C |
| Paediatric rheumatology | 232 | Naeem Ullah | Pediatric Rhupus Syndrome: A Narrative Review of the Clinical Features, Diagnosis, and Management of JIA and SLE Overlap. | 2 | C |
| Paediatric rheumatology | 233 | ChaoYi Wu | Clinical Practice Consensus Guidelines for Childhood-Onset Systemic Lupus Erythematosus in Taiwan | 2 | C |
| Paediatric rheumatology | 234 | Belina Yi | Methodology report: International recommendations for the management of juvenile idiopathic inflammatory myopathies, an IMACS-CARRA-PReS cross-party initiative, supported by Cure JM. | 2 | C |
| Paediatric rheumatology | 235 | Napapas Yothakol | Cardiac Tamponade in Microscopic Polyangiitis: A Rare but Potentially Life-Threatening Manifestation | 2 | C |
| Paediatric rheumatology | 236 | Napapas Yothakol | Sleep Disturbances in Thai children and adolescents with Juvenile Idiopathic Arthritis | 2 | C |
| Paediatric rheumatology | 237 | Valeriya Yudina | Tocilizimab efficacy in the treatment of non‑systemic juvenile idiopathic arthritis in real clinical practice in Russia | 2 | C |
| Precision medicine | 238 | DerYuan Chen | Machine learning-based identification of a novel panel for predicting “Difficult-to-Treat” rheumatoid arthritis by integrating WES-derived genetic markers and clinical phenotypes | 2 | C |
| Psoriatic arthritis | 239 | Stanley Angkodjojo | Sex differences in Baseline Phenotype and Multidomain Disease Burden in a Singapore Psoriatic Arthritis Cohort | 2 | C |
| Psoriatic arthritis | 240 | Sunith Himantha Atukorale | Diagnostic Delay and Psychological Burden in Psoriatic Arthritis | 2 | C |
| Psoriatic arthritis | 241 | Isaac Tsz Ho Cheng | Association of healthcare disparities and disease activity and impact in Psoriatic arthritis across 13 Asian countries | 2 | C |
| Psoriatic arthritis | 242 | Princess Joy Estrella | Severe Psoriatic Arthritis Across Reproductive Transition: Remission With Golimumab Followed by Pregnancy — A Case Report | 2 | C |
| Psoriatic arthritis | 243 | Yu Fu | The Role and Mechanisms of Interferon-Induced Neutrophils in the Pathogenesis of Psoriatic Arthritis | 2 | C |
| Psoriatic arthritis | 244 | Alex Garaiman | Lighten the Load: Body Mass Index Outweighs Treatment in One-Year Psoriatic Arthritis Outcomes—Post Hoc Findings from the SPEED Trial | 2 | C |
| Psoriatic arthritis | 245 | Hyerim Jin | Comparative Effectiveness of Risankizumab Versus TNF or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve PsA Patients: A Real-World Study | 2 | D |
| Psoriatic arthritis | 246 | Hyerim Jin | Real-World Comparative Effectiveness of Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Skin Symptoms in Psoriatic Arthritis | 2 | D |
| Psoriatic arthritis | 247 | Kamil Khayrutdinov | Successful Combination Therapy of Psoriatic Arthritis and Psoriasis with IL-23, Janus Kinase Inhibitors as an Eighth Line of Biologic/Targeted Therapy | 2 | D |
| Psoriatic arthritis | 248 | Mitsumasa Kishimoto | Bimekizumab inhibited radiographic progression in bDMARD-naïve patients with active psoriatic arthritis: 3-year results from phase 3 study and open-label extension | 2 | D |
| Psoriatic arthritis | 249 | Mitsumasa Kishimoto | Study design of phase 3 randomized, double-blind, multicenter trials of zasocitinib in patients with active psoriatic arthritis (LATITUDE-PsA-3001 and 3002) | 2 | D |
| Psoriatic arthritis | 250 | Inna Klimovich | Features of Axial Skeleton Involvement and Diagnostic Methods in Psoriatic Arthritis | 2 | D |
| Psoriatic arthritis | 251 | Tatiana Korotaeva | A method for predicting the achievement of an acceptable symptom state in patients with psoriatic arthritis | 2 | D |
| Psoriatic arthritis | 252 | Tatiana Korotaeva | Effectiveness of IL17 inhibitor (Netakimab) in treating patients with psoriatic arthritis and spondylitis: the results of SIRIUS multicenter observational study | 2 | D |
| Psoriatic arthritis | 253 | Tatiana Korotaeva | Impact of body mass index on Netakimab treatment response in psoriatic arthritis: post-hoc analysis of the SIRIUS multicenter observational study | 2 | D |
| Psoriatic arthritis | 254 | Tatiana Korotaeva | Netakimab, a IL17-inhibitor, effectiveness, 2-years treatment survival and safety profile in psoriatic arthritis patients: the results of SIRIUS observational study | 2 | D |
| Psoriatic arthritis | 255 | Tatiana Korotaeva | Predictors of achieving a patient acceptable symptom state in psoriatic arthritis. Data from 7 years follow-up | 2 | D |
| Psoriatic arthritis | 256 | Tatiana Korotaeva | The effectiveness of netakimab, a IL17 inhibitor, in psoriatic arthritis patients with comorbidities: the results of SIRIUS observational study | 2 | D |
| Psoriatic arthritis | 257 | Remson Lopena | A Flare Transformed: Secukinumab in Erythrodermic Psoriasis | 2 | D |
| Psoriatic arthritis | 258 | Thomas Mandl | Bimekizumab time to meaningful improvements in clinical/patient-reported outcomes in patients with psoriatic arthritis: results from two phase 3 studies | 2 | D |
| Psoriatic arthritis | 259 | Ejim Mark | Bone formation and inflammatory biomarkers associated with clinical response in Phase 2b trial of zasocitinib (TAK-279) in active psoriatic arthritis | 2 | D |
| Psoriatic arthritis | 260 | Ejim Mark | Phase 2b trial of zasocitinib (TAK-279) in active psoriatic arthritis: biomarkers associated with pathway modulation, disease activity and clinical responses | 2 | D |
| Psoriatic arthritis | 261 | Kaoru Minegishi | Skin Sodium Accumulation by 23Na-MRI as a Potential Imaging Biomarker in Psoriatic Arthritis | 2 | D |
| Psoriatic arthritis | 262 | Muhammad Shoaib Momen Majumder | Metabolic Multimorbidity and Cardiovascular Risk in Psoriatic Arthritis: A Case–Control Study from Bangladesh | 2 | D |
| Psoriatic arthritis | 263 | KAMKA OMAROVA | Mechanism-Based IL-23 Blockade Achieves Multidomain Remission in Difficult-to-Treat Psoriatic Disease | 2 | D |
| Psoriatic arthritis | 264 | Kyaw Naing Oo | Anti-TNF inhibitor induced Alopecia Areata in psoriatic arthritis and its effective management | 2 | D |
| Psoriatic arthritis | 265 | Surendran Ramasamy | Triple Therapy for Life-Threatening Rapidly Progressive Interstitial Lung Disease in Psoriatic Arthritis: A Case Report | 2 | D |
| Psoriatic arthritis | 266 | Yoshiya Tanaka | Bimekizumab efficacy & safety versus risankizumab over 16 weeks in patients with psoriatic arthritis | 2 | D |
| Psoriatic arthritis | 267 | Yoshiya Tanaka | Bimekizumab efficacy & safety versus risankizumab over 16 weeks in patients with psoriatic arthritis and no to mild psoriasis | 2 | D |
| Psoriatic arthritis | 268 | Yoshiya Tanaka | Bimekizumab maintained clinical efficacy responses to 3 years in patients with active psoriatic arthritis across two phase 3 studies | 2 | D |
| Psoriatic arthritis | 269 | Yoshiya Tanaka | Bimekizumab treatment demonstrated long-term efficacy and safety in biological-naïve patients with active psoriatic arthritis: Week 192 results from BE OPTIMAL | 2 | D |
| Psoriatic arthritis | 270 | Haoming Tang | Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis | 2 | D |
| Psoriatic arthritis | 271 | Alena.I. Zagrebneva | Real-World Effectiveness and Treatment Persistence of Guselkumab in Patients with Psoriatic Arthritis: Data from the Moscow City Registry | 2 | D |
| Psoriatic arthritis | 272 | Xiaofeng Zeng | Efficacy and safety of deucravacitinib in active psoriatic arthritis: pooled Asian population subgroup analysis of POETYK PsA-1 and PsA-2 studies | 2 | D |
| Scleroderma, myositis and related syndromes | 273 | Queency Joy Batucan | Anti-mda5 antibody–positive dermatomyositis interstitial lung disease: a case series of its three phenotypes | 2 | D |
| Sjogren syndrome | 274 | Weilu Chen | PSMB9 is a target associated with mitochondrial dysfunction in Sjogren's syndrome: insights from integrating multi-omics, Mendelian Randomization, and transcriptome analysis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 275 | Sakir Ahmed | Effectiveness and Safety of Sequential Therapy of Infliximab and Tofacitinib in Axial Spondyloarthritis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 276 | Stanley Angkodjojo | From skin to gut in axial spondyloarthritis: Paradoxical biologic reactions and mechanism-based therapeutic sequencing | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 277 | Yunus Emre Dalkılıç | The Tofacitinib Experience in Spondyloarthritis: Could the Presence of Fibromyalgia Alter Treatment Strategies | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 278 | Natasha De Peyrecave | Minimal Spinal Radiographic Progression in Chinese Patients with Radiographic Axial Spondyloarthritis over Two Years with Bimekizumab Treatment | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 279 | Tatiana Dubinina | Efficacy and safety of Upadacitinib in patients with active ankylosing spondylitis in real clinical practice | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 280 | Tatiana Dubinina | Efficacy of Seniprutug in patients with active radiographic axial spondyloarthritis: data from real clinical practice | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 281 | Tatiana Dubinina | Long-term Comparative Effectiveness of Netakimab Versus biologic and target synthetic DMARDs in Active Radiographic Axial Spondyloarthritis: Simulated Treatment Comparisons | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 282 | Tatiana Dubinina | Safety of Personalized Dosing Regimens of Seniprutug, a TRBV9+ T-Cell Depleting Monoclonal Antibody, in Radiographic Axial Spondyloarthritis: ELEFTA Study Results | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 283 | Tatiana Dubinina | Seniprutug, a TRBV9+ T-Cell Depleting Monoclonal Antibody, from clinical research to real practice | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 284 | Inna Gaydukova | Combined Biological and Targeted Therapy in Difficult-to-Treat Rheumatoid, Psoriatic, and Spondyloarthritis Patients: A 20-Case Real-World Analysis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 285 | Inna Gaydukova | Low rate of uveitis exacerbation in axial spondyloarthritis patients treated with netakimab: real-world data from the LIBRA cohort | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 286 | Juan Raphael Gonzales | Biopsy-Proven IgA Nephropathy in a Patient with Ankylosing Spondylitis Receiving Infliximab: A Case Report | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 287 | Jieruo Gu | Sustained Improvements with Bimekizumab in Patient-Reported Symptoms and Quality of Life in Chinese Patients with Axial Spondyloarthritis over Two Years | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 288 | Jinxian Huang | Multi-omics sequencing analysis of plasma exosomes in patients with ankylosing spondylitis after adalimumab treatment and investigation of potential regulatory mechanisms | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 289 | Hyerim Jin | Extra-Musculoskeletal Manifestations in Upadacitinib-Treated Spondyloarthritis: Long-Term Clinical Trial and Real-World Data | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 290 | Hyerim Jin | How quickly do pain, global functioning and health improve with upadacitinib in real-world axial spondyloarthritis? | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 291 | Hyerim Jin | Impact of Upadacitinib on Non-Nociceptive Pain and Residual Symptoms in Axial Spondyloarthritis: Real-World Study | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 292 | Elizaveta Kashina | Evaluation of anti CD74 IgA as a predictor of non response to biological treatment in axial spondyloarthritis. | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 293 | Elizaveta Kashina | IgA anti-CD74 antibodies as a CRP-independent marker of disease burden in difficult-to-treat axial spondyloarthritis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 294 | YoungEun Kim | Long-Term Routine Laboratory Toxicity Monitoring in Spondyloarthropathy During Treatment with Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 295 | Mitsumasa Kishimoto | Long-term uveitis rates in bimekizumab-treated patients with axial spondyloarthritis or psoriatic arthritis across pooled phase 2b/3 studies: 3-year update | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 296 | Mitsumasa Kishimoto | Safety and Tolerability of Bimekizumab in Asian Populations with Axial Spondyloarthritis or Psoriatic Arthritis: 1-Year Results from Phase 3 Studies | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 297 | Mitsumasa Kishimoto | Time to Meaningful Improvements with Bimekizumab in Patients with Axial Spondyloarthritis: Post Hoc Analysis of Two Pooled Phase 3 Studies | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 298 | Alesia Klimenko | Personalized Dosing Regimens of Seniprutug (BCD-180), a TRBV9+ T-Cell Depleting Monoclonal Antibody: Efficacy Results from the Phase II ELEFTA Study | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 299 | Tatiana Korotaeva | Efficacy of Netakimab in Axial manifestations of Psoriatic Arthritis and Ankylosing Spondylitis: A Post-hoc Pooled Analysis from Placebo-Controlled Clinical Trials | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 300 | Tatiana Korotaeva | Netakimab Efficacy in Patients with Axial Spondylarthritis: Pooled Analysis from the Randomized Placebo-Controlled Phase 3 BCD-085-5/ASTERA and BCD-085-8/PATERA Clinical Studies | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 301 | SVETLANA LAPSHINA | Long-Term Netakimab Therapy Demonstrates Sustained Prevention of Radiographic Progression in Ankylosing Spondylitis: 156-Week Results from the Phase III ASTERA Trial | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 302 | SVETLANA LAPSHINA | Maintenance of remission after discontinuation of netakimab in patients with ankylosing spondylitis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 303 | Xianming Long | Efficacy and Safety of Ivarmacitinib in the Treatment of a Patient with Refractory Ankylosing Spondylitis: A Case Report | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 304 | Seoung Wan Nam | Efficacy and Safety of a 12-Week Taekwondo-Based Exercise Program in Patients with Axial Spondyloarthritis: A Pilot Randomized Controlled Trial | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 305 | Peter Nash | Bimekizumab-treated patients with axial spondyloarthritis maintained stringent clinical responses over 3 years: results from phase 3 studies and open-label extension | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 306 | Peter Nash | Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis or psoriatic arthritis: 3-year update from phase 3 studies | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 307 | Ping Seung Ong | Influence of biologic therapy on lipid profiles in axial spondyloarthritis: insights from multicentre longitudinal study | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 308 | Hee Won Park | Drug survival of TNF, IL-17, and JAK inhibitors in biologic-experienced patients with ankylosing spondylitis: data from the KOBIO registry | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 309 | Abdurrahman Soner Senel | The influence of HLA-B27 status on initial biologic selection and time to initiation of bDMARD therapy in patients with axial-spondyloarthritis | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 310 | K Shanmuganandan | Comparative Study of Tofacitinib with Adalimumab in case of Spondyloarthritis in Teritary care center | 2 | D |
| Spondylarthropathies biological and non-biological therapies | 311 | Pavel Shesternya | Seniprutug safety and effectiveness profile in patients with active radiographic axial spondyloarthritis | 2 | E |
| Spondylarthropathies biological and non-biological therapies | 312 | Chang-Nam Son | Complement factor H-related protein 5 enhances osteoblast differentiation | 2 | E |
| Spondylarthropathies biological and non-biological therapies | 313 | Elizaveta Vasilenko | A First-in-Class Anti-TRBV9 Therapy in Ankylosing Spondylitis: 48-Week Real-World Clinical and Laboratory Outcomes | 2 | E |
| Spondylarthropathies biological and non-biological therapies | 314 | Chunrong Wang | Efficacy and safety of netakimab in Chinese patients with radiographic axial spondyloarthritis: a randomized, double-blind phase 3 study | 2 | E |
| Spondylarthropathies biological and non-biological therapies | 315 | Jiwon Yang | Predictors of Treatment Response to IL-17 Inhibitors in Patients with Axial Spondyloarthritis: A Multicenter Real-World Longitudinal Study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 316 | Bernadette Abejon | A Young Heart Under Pressure: Systemic Lupus Erythematosus with Pulmonary Hypertension and Pericardial Effusion Complicated by Tuberculous Meningitis | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 317 | Hanan Al Rayes | The Effect of Ramadan Fasting on Systemic Lupus Erythematosus and Lupus Nephritis Activity: An Observational Study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 318 | Damir Aliev | Clinical and immunological features of systemic lupus erythematosus in Patients with high expression of interferon gene signature | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 319 | Amira Elina Amirul Iskandar | Association between STAT4 Polymorphisms and Clinical Characteristics, Disease Activity, and Organ Damage in a Malay SLE Cohort | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 320 | Amira Elina Amirul Iskandar | Reduced STAT4 Expression Independent of Disease Activity and Low Detectable Circulating IFN-γ and IL-17A in a Malay SLE Case-Control Cohort | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 321 | Amira Elina Amirul Iskandar | STAT4 Polymorphisms, Gene Expression and Risk of SLE among Malay Patients: A Population-Specific Case-Control Study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 322 | Iana Katrina Antipuesto | Intestinal Tuberculosis Presenting as Massive Hematochezia in a Patient with Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 323 | Hairul Hadi Ariff | Durable Remission in SLE: Real-World Insights from Sabah | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 324 | Hairul Hadi Ariff | Durable Remission in Systemic Lupus Erythematosus in Sabah: Real-World Outcomes Using the DORIS Framework | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 325 | Sri Safariyawati Maidina Asyahrul Afif | Fahr’s syndrome in systemic lupus erythematosus patient- a case report | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 326 | Fhathia Avisha | Cytomegalovirus Bone Marrow Infection Presenting as Recurrent Bicytopenia in Systemic Lupus Erythematosus: A Case Report | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 327 | Bodhibrata Banerjee | Clinical Spectrum, Mechanistic Insights, and Outcomes of Thrombotic Microangiopathy in Rheumatic Diseases: Experience From A Tertiary Care Centre In India | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 328 | Maira Bizhanova | Clinical Characteristics and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus in Kazakhstan | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 329 | Rufaidah Pharmanisa Boriongan | When lupus attacks all fronts: a rare case of fulminant multi-organ SLE responding to aggressive multimodal therapy | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 330 | Cherizh Joane Calantoc | From Chronic Diarrhea to Transverse Myelitis: An Unusual and Debilitating Presentation of Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 331 | Madhuri Challa | Clinical Spectrum and Determinants of Tuberculosis in Patients with Systemic Lupus Erythematosus: A Hospital-Based Case-Control Study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 332 | Manikandan Chidambaram | Iron deficiency anemia in systemic lupus erythematosus: prevalence and outcomes following iron supplementation | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 333 | Shannon Chin | Risk factors for lupus nephritis in a multi-ethnic Asian cohort | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 334 | In Ah Choi | Patient knowledge, perspectives, and behaviors related to cervical cancer prevention and screening among Korean women with systemic lupus erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 335 | Anna Krystel Chua | Gastrointestinal and Neurological Catastrophes: A Rare Case of Lupus-Associated Protein-Losing Enteropathy and Transverse Myelitis | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 336 | Carl Kasten Cocson | Wolf in Early Gestation: Case of New-Onset Systemic Lupus Erythematosus with Cardiac Tamponade Diagnosed in the First Trimester of Pregnancy | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 337 | Faizullo Davlatov | Prognostic Significance of Disease Activity and Lupus Nephritis for Cardiovascular Outcomes in Patients with Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 338 | Erwin Dharmawan | Immune-Mediated Coronary Thrombosis Presenting as MINOCA in Active Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 339 | Manasa Dixit | Meta-analytic clustering of SLE autoantibodies to characterize organ-specific involvement and quantify associated relative risk | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 340 | Asena Eken | Predominance of Systemic Lupus Erythematosus and Sjögren's Disease in Anti-Ku Positivity: A Clinical Cohort Analysis | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 341 | Paul Etau Ekwom | Cutaneous manifestation of lupus and disease progression in patients seen at dermatology and rheumatology departments - Kenyatta national hospital | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 342 | Neil Gabriel Encina | Clinical-Histologic Discordance of Systemic Lupus Erythematosus with IgA-Dominant Membranoproliferative Glomerulonephritis: A Case Report | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 343 | Yao Fan Fang | High Immunological Activity but Limited Prognostic Value for Organ Damage: Re-evaluating the Role of Anti-SSA/SSB Antibodies in Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 344 | Hrishikesh Nagbhushan Gangule | Albumin- versus protein-based indices for longitudinal monitoring of lupus nephritis progression and response | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 345 | Hrishikesh Nagbhushan Gangule | Diagnostic and prognostic utility of urinary albumin-creatinine ratio in lupus nephritis: a histopathological correlation study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 346 | Shiaianne Genolos | Diffuse Alveolar Hemorrhage in a 20-year-old patient with Systemic Lupus Erythematosus: A Case Report | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 347 | Shiaianne Genolos | Fetal, maternal and pregnancy outcomes among pregnant Filipinos with autoimmune rheumatic diseases in a tertiary hospital: a retrospective study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 348 | Shiaianne Genolos | Shrinking lung syndrome in a 25-year old Filipino female with systemic lupus erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 349 | Juan Raphael Gonzales | Clinical Spectrum of Thrombotic Thrombocytopenic Purpura in Patients with Systemic Lupus Erythematosus: A Case Series | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 350 | Chagalakondu Guru Vijay | Inflammation Versus Lipid-Derived Risk Markers in Subclinical Atherosclerosis Among Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 351 | Laniyati Hamijoyo | Characteristics and Factors associated with Remission of Systemic Lupus Erythematosus Patients in Indonesia | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 352 | Laniyati Hamijoyo | Factors Associated with Indeterminate IGRA Results for Latent Tuberculosis in Patients with Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 353 | Jieun Han | Oral administration of germanium telluride nanosheets inhibits plasma cell differentiation and attenuates nephritis in lupus-prone mice | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 354 | Maho Hatano | Age-related differences and clinical clusters of systemic lupus erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 355 | Karunanayaka H D T Hemachandra | A case of angioedema-rare presentation of Systemic Lupus Erythematosus | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 356 | Hwee Siew Howe | Ethnic Variation in Clinical Phenotypes of Systemic Lupus Erythematosus in a Multi-Ethnic Singapore Cohort(single) | 2 | E |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 357 | Tsu-Yi Hsieh | High Rate of Class Transformation in Class IV lupus nephritis in Chinese, by per-protocol re-biopsies but not in on-demanded rebiopsy. | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 358 | Teng-Chieh Hsu | Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: An Emulated Target Trial | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 359 | Nadyatul Husna | Integrative Multi-Omic Signatures of Interferon and Epigenetic Dysregulation Predicting Renal Involvement in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 360 | Nobuaki Iwakura | Statin use and renal function trajectories in chronic kidney disease with lupus nephritis: luna registry | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 361 | Gene Paolo Jasmin | When Autoimmunity Overlaps: A Case of Systemic Lupus Erythematosus with Neuro-Ophthalmic Involvement in a Patient with Multiple Sclerosis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 362 | Kanisa Jitpanya | Effectiveness of acyclovir prophylaxis for herpes zoster prevention in systemic lupus erythematosus: a retrospective cohort study with time-varying analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 363 | Dong Wook Ju | Differential Impact of Perceived Social Support and Disease Activity on Depression and Fatigue in Korean Patients with Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 364 | Gail Kerr | Ozone and fine particulate matter components of air pollution are associated with systemic lupus erythematosus (SLE) risk | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 365 | Parichat Khaosut | Characteristics and Associated Risk Factors of Opportunistic Infection in Children with Systemic Lupus Erythematosus in Under-Resourced Areas | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 366 | YoungEun Kim | Bone Marrow Activity on 18F-FDG PET/CT: A Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 367 | Wonngarm Kittanamongkolchai | Clinical Characteristics and Predictors of Prolonged Drug-Free Remission in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 368 | Panupong Kongkiatsin | Complete Remission Rate and Predictive Factors of Complete Remission in Lupus Nephritis: A 12-Year Retrospective Cohort Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 369 | Takeshi Kuroda | Clinical background factors related to silent osteonecrosis of the femoral head upon initiation of steroid therapy in patients with SLE | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 370 | Karll Denzel Lao | Spinal Tuberculosis Mimicking Neuropsychiatric Lupus in a Male Patient with Systemic Lupus Erythematosus: A Case Report | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 371 | Yeo-jin Lee | Inhibition of Renal Macrophage Infiltration by Allopurinol Mitigates Disease Activity in MRL/lpr Mice | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 372 | Qi Dong Leong | Newly-diagnosed Systemic Lupus Erythematosus in a 62-year-old male presenting with Distal Renal Tubular Acidosis: A Case Report | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 373 | Yu-Hsien Li | Association between Dust Mite Sensitization and Cutaneous Disease Severity in Patients with Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 374 | Yujing Li | Choroidopathy as the Initial Manifestation of Systemic Lupus Erythematosus: Two Cases with Literature Review | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 375 | Yujing Li | IFI44L Promoter Methylation as a Biomarker Across the Spectrum of SLE: From Genetic Predisposition to Diagnosis and Disease Activity Monitoring | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 376 | lu Liu | SAT1 p.D40Y Missense Mutation Participates in the Pathogenesis of Systemic Lupus Erythematosus by Regulating Macrophage Metabolic Reprogramming via Polyamine Metabolism | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 377 | Michael Lusida | Metabolic profile and arterial stiffness in SLE patients with Low disease activity in a tertiary hospital in Indonesia | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 378 | Mahabaleshwar Mamadapur | Hydroxychloroquine Blood Concentration in Systemic Lupus Erythematosus: Lupus Flares, Patient Adherence, and Therapeutic Monitoring | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 379 | Mia Mangahas | A case report of a 42-year-old, Female with Purtscher-like Retinopathy, an Exceedingly Rare Ocular Manifestation of Systemic Lupus Erythematosus. | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 380 | Hong Ki Min | Risk of cognitive disorders in patients with primary Sjögren syndrome: data from Korean health insurance service | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 381 | Khilola Mirakhmedova | Diagnostic and Clinical Significance of Serum levels of PON1 and IL-6 in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 382 | Dezza Montejo | Mapping the burden of lupus: a network analysis of quality of life among Filipino patients using lupuspro | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 383 | Tatiana Panafidina | Antithyroid antibodies and thyroid dysfunction in women with systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 384 | Tatiana Panafidina | Clinical significance of complement in systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 385 | Tatiana Panafidina | Clinical significance of criterial and non-criterial autoantibodies and IFN-I in systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 386 | Tatiana Panafidina | Diabetes mellitus - associated antibodies in women with systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 387 | ayu Paramaiswari | Correlation Between Routine Laboratory Parameters and Renal Biopsy Histopathological Indices in Lupus Nephritis: A Cross-Sectional Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 388 | Tiara Nien Paramita | Malnutrition Matters: Nutritional Trajectories and Disease Activity One Year After Diagnosis in Childhood-Onset Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 389 | Jingyi Peng | Glomerulosclerosis Score as a Superior Predictor of Longitudinal Renal Functional Decline and Survival in Lupus Nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 390 | Prapaporn Pisitkun | Association of GSTT1 and GSTP1 Polymorphisms with Infection Risk During Cyclophosphamide Induction Therapy in Patients with Active SLE | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 391 | Evgenii Pletnev | Clinical features of 1102 patients with systemic lupus erythematosus in the Russian Federation, Kirgizstan and Kazakhstan | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 392 | Evgenii Pletnev | Relationship Between Disease Activity, Organ Damage and Health-Related Quality of Life as Assessed by LupusQoL and SF-36 | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 393 | Tatiana Popkova | Dynamics of Left Ventricular Global Longitudinal Strain in Patients with Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 394 | Tatiana Popkova | Pulse Wave Velocity in Patients with Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 395 | Tatiana Popkova | Systemic lupus erythematosus in male patients | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 396 | Tatiana Popkova | The serum level of TNF-α type 2 receptor in patients with SLE | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 397 | Widya Pratiwi | Galectin-9 as a biomarker of disease activity in systemic lupus erythematosus: a systematic review and meta-analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 398 | Widya Pratiwi | Is Cardiac Tamponade an Emerging Concern in Systemic Lupus Erythematosus? A Global Bibliometric Analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 399 | Ng Qi-Wei | Clinical Manifestations and 10-Year Disease Trajectories in Early-Onset versus Late-Onset SLE: Evaluating the Role of Prednisolone in the iLUPUS Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 400 | Ng Qi-Wei | MHC Fine-Mapping Analysis Identifies Independent Susceptibility and Anti-dsDNA Antibody Markers in Malay Patients with SLE: Insights from the iLUPUS Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 401 | Melvin Ramos | Role of Rituximab in Purtscher-like Retinopathy: An Ocular and Hematologic Manifestations in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 402 | Rafly Mochamad Rivaldo | Integrated Bioinformatics Transcriptomic and Immune Cell Analysis Reveals Common Molecular and Immunopathogenic Mechanisms in Both Tuberculosis and Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 403 | Rila Rivanda | Severe Lupus Nephritis Flare During First-Trimester Pregnancy Complicated by Acute Kidney Injury, Refractory Hyperkalemia and Serositis: a Multisystem Therapeutic Challenge | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 404 | Zomuan Sanga | The Great Mimicker Unveiled: SLE with Secondary HLH/MAS Masquerading as Brucellosis, Complicated by Atypical Esophageal Candidiasis – A Diagnostic Odyssey | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 405 | Avishek Sarangal | Striatal Encephalitis as a Rare Neuropsychiatric Manifestation of Systemic Lupus Erythematosus: Diagnostic Challenges and Importance of Sequential Immunosuppressive Therapy | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 406 | Chika Sasakura | Antiphospholipid Antibody Profiles and Pregnancy Outcomes in Systemic Lupus Erythematosus: A Japanese Multi-Center Prospective Cohort Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 407 | Athira Sasidharan | A clinical dilemma: Balancing immunosuppression and infection risk in treating SLE flare versus polyresistant Tuberculosis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 408 | Muhammedu Muees Shahana | First Presentation of Systemic Lupus Erythematosus as Bilateral Periorbital Swelling – A Rare Presentation with Diagnostic Challenge | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 409 | Ishita Singh | Prognostic Value of Baseline Left Ventricular Strain in Systemic Lupus Erythematosus: A 10-Year Prospective Cohort Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 410 | Prachi Singh | Clinical Phenotype and Morbidity Associated with Viral Infections in Patients with Systemic Lupus Erythematosus: A Retrospective Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 411 | Aabishkar Subedi | Immunofluorescence Antinuclear Antibody Patterns and Clinical Correlations in Systemic Lupus Erythematosus Patients: A Study from a Tertiary Center in Nepal | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 412 | Ramaswamy Subramanian | Fertility and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Prospective Single-Centre Registry Analysis from South India | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 413 | Shadab Saud Sunny | Gender-Based Differences in Clinical, Immunological and Disease Activity Profiles of Systemic Lupus Erythematosus Patients in Bangladesh | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 414 | Emil Andrew Tablante | Late-Onset Systemic Lupus Erythematosus with Secondary Antiphospholipid Syndrome in an Elderly Male: A Diagnostic Challenge | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 415 | Katsunori Takahashi | Validation study of Systemic Lupus Erythematosus Diagnosis Codes using Japanese Administrative Claims Data: A Pilot Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 416 | Alyanna Pauline Tambuli | Fear of childbirth among adult reproductive age women diagnosed with systemic lupus erythematosus in a tertiary hospital in the Philippines | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 417 | Eshan Taneja | When Numbers Mislead: A Hidden Hemostatic Defect in SLE | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 418 | Mayuka Tanimura | Serologically Active Clinically Quiescent Status and Serological Profiles as Predictors of Clinical Worsening in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 419 | Iyan Tarigan | Correlation of obesity indicators with disease activity based on the clinical systemic lupus erythematosus disease activity index 2000 (csledai-2K) | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 420 | Alveron Andreas Tear | Risk factors of microbiologically confirmed bacterial infection in SLE patients: a systematic review and meta-analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 421 | Michael Tee | An Integration of Diet, Gut Microbiome and Genetics on the Status of Systemic Lupus Erythematosus among Filipino Patients | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 422 | Bernard Thong | Real-world management of acute SLE-related non-cirrhotic portal hypertension (SLE-NCPH) | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 423 | Hiroshi Tsushima | Physician Burnout is Associated with Lower Patient Trust in SLE Care: A Multicenter Study from the TRUMP2-SLE Project | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 424 | Meruert Usmanova | Cardiac-dominant systemic lupus erythematosus presenting with Libman-Sacks endocarditis complicated by pulmonary hypertension: a case of delayed diagnosis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 425 | Fabien Vincent | Resistant Hypertension in Systemic Lupus Erythematosus: A Single-Centre Retrospective Cohort Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 426 | Fabien Vincent | Untargeted serum proteomics in patients with systemic lupus erythematosus reveals molecular pathways associated with ethnicity and disease phenotypes | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 427 | Evan Vista | Tuberculosis Risk, Spectrum, and Determinants in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 428 | Khuan Wai Hou | Acute Bowel Ischemia from Lupus Enteritis as The Initial Presentation of Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 429 | Kiran Wakade | When Full House Does Not Mean Lupus: A Case-Based Insight | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 430 | Chun Chun Wang | Profiles of Patients with Lupus Nephritis Receiving Belimumab Under NHIA Criteria in Taiwan: Interim Analysis of the REBOUND Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 431 | Fangqing Wang | Clinical and Immunological Characteristics and Prognostic Model Construction of Patients with Late-Onset Systemic Lupus Erythematosus in China | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 432 | Kai Chun Wang | High Burden of Coinfection in Systemic Lupus Erythematosus with Bronchoalveolar Lavage Confirmed Pneumocystis jirovecii Pneumonia: A Single-Center Retrospective Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 433 | Ming Wang | Antiphospholipid Antibodies in Chinese Women Resembling Obstetric Antiphospholipid Syndrome: A National Multicenter Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 434 | Welly Wijaya | Evaluating The Correlation Between SII and MEX-SLEDAI Scores Among Patients with Systemic Lupus Erythematosus: A Rheumatology Outpatient Setting | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 435 | Maha Chakri Willheljulya | Paroxysmal nocturnal haemoglobinuria (PNH) and systemic lupus erythematosus (SLE): a case of coincidence? | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 436 | Takayuki Yotsuyanagi | Time-Dependent Prediction serological markers of Non-Reassuring Fetal Status in SLE Pregnancy | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 437 | Nurul Aulia Zakaria | Hidden Lupus: Extensive Portal and Mesenteric Vein Thrombosis (PMVT) in Late-Onset SLE | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 438 | Yichi Zhang | Association between antiphospholipid antibody profile and serological disease activity in patients with systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 439 | Anel Zhumabek | Young-Onset Systemic Lupus Erythematosus with Secondary Antiphospholipid Syndrome and Visceral Malposition | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 440 | Eric Morand | Content validity of an 11-point chest pain Numerical Rating Scale (NRS) as a Patient-Reported Outcome (PRO) measure in SLE serositis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 441 | Eric Morand | Low Disease Activity and Remission in Systemic Lupus Erythematosus with Dapirolizumab Pegol: Analyses from a 48-Week Phase 3 Trial | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 442 | Hairul Hadi Ariff | Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Single-Centre Case Series from Malaysia | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 443 | Ingrid Astronomia | Eosinophilic Granulomatosis with Polyangiitis Associated with Autoimmune Hemolytic Anemia: A Rare Diagnostic Overlap | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 444 | Geianne Renci Atienza | Takayasu Arteritis with Multiple Arterial Involvement: A Case Report | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 445 | Olivia Beazer | Patterns of weight gain during glucocorticoid treatment for giant cell arteritis: an audit from two UK rheumatology clinics. | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 446 | Tatiana Beketova | Direct interleukin-6 inhibitor olokizumab in the treatment of Giant Cell Arteritis and Polymyalgia Rheumatica | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 447 | Christopher Bell | A case of a novel MYH11 variant presenting with distal Internal Carotid Artery dissection and mimicking Giant Cell Arteritis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 448 | Nidhi Bhutra | Ulcers That Defy Labels: A Clinicopathological Diagnostic Challenge | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 449 | Jude Philip Cebrecus | Ruptured Left Common Femoral Artery Aneurysm as an Initial Presentation of Giant Cell Arteritis: A Case Report | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 450 | Kazuki Chida | Achievement of Deep Clinical Remission and Subsequent Relapse in MPO-ANCA–Positive Microscopic Polyangiitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 451 | Stephanie Dajuela | Unraveling the Intracranial Mysteries of Takayasu Arteritis: A Case of Multiple Cranial Nerve Deficits | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 452 | Joseph Danicic | Immunoglobulin A vasculitis in association with invasive meningococcal disease: a case report. | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 453 | Niharika Dubey | When Eosinophilia Mimics Embolic Stroke: A Neurovascular Presentation of Eosinophilic Granulomatosis with Polyangiitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 454 | Aayush Dukiya | When Pancreatitis Isn’t Pancreatitis: A Rare Pancreatic Onset p-ANCA Vasculitis with Evolving Multisystem Clinical Presentation | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 455 | Mary Joanne Garchitorena | Clinical Profile and Outcomes of Patients with Takayasu Arteritis: A Multicenter Study in the Philippines | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 456 | Muneyuki Hatta | Pretreatment neutrophil-to-lymphocyte ratio is associated with clinical phenotype and infection-related mortality in microscopic polyangiitis: analysis from the REVEAL cohort | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 457 | Tsu-Yi Hsieh | Biphasic Presence of Malignancies in Patients with ANCA-associated Vasculitis in Taiwan: a case series of tertiary referral centers | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 458 | Kazuma Ino | Real-world data of the efficacy and safety of avacopan for ANCA-associated vasculitis: a single-center, retrospective cohort study. | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 459 | Anjana Jayan | When Infection Misleads :ANCA- Associated Vasculitis with a False Positive Fungal Marker | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 460 | Jack Jeffries | Performance of the Southend Giant Cell Arteritis Pre-Test Probability Score in an Australian Cohort | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 461 | Hyerim Jin | Clinical Characteristics of Flares of Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 462 | Hiroshi Kataoka | The potential of Anti-IL5 therapy for Sinonasal Lesions in Eosinophilic Granulomatosis with Polyangiitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 463 | Toshio Kawamoto | Optimization of Imaging Diagnosis for Giant Cell Arteritis According to Clinical Phenotype | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 464 | alireza Khabbazi | Body Mass Index and Risk and Outcomes of Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 465 | Mikhail Kostik | HCV-Associated Cryoglobulinemic Vasculitis With Polyneuropathy and Advanced Liver Fibrosis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 466 | Yujing Li | Pulmonary Granulomatosis with Polyangiitis: Longitudinal Imaging of Lesion Evolution under B-Cell–Targeted Therapy | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 467 | Joseph Peter Lim | Takayasu Arteritis in a Young Male with Combined Aneurysmal and Stenotic Large Vessel Disease | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 468 | Lianzeran Liu | Navigating the Immunosuppression-Infection Dilemma in ANCA-Associated Vasculitis with Diffuse Alveolar Hemorrhage and renal dysfunction: A Case Guided by Renal Histopathology | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 469 | Gowri Manoharan | Myopathy as the Presenting Manifestation of ANCA-Associated Vasculitis: A Retrospective Case Series | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 470 | Naina Mehta | When Lupus Isn’t Lupus: Cryoglobulinemic Glomerulonephritis with Secondary TMA Revealing Primary Sjögren’s Syndrome | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 471 | Dikshaladevi Nisanthan | Refractory Granulomatosis with Polyangitis: A therapeutic challenge overcome by sequential immunosuppression | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 472 | Sopita Nuansuwan | Comparison of clinical characteristics and outcomes in younger- and elderly-onset ANCA-associated vasculitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 473 | Hiroshi Oiwa | Alveolar Hemorrhage in ANCA-Associated Vasculitis in a Community-Based Hospital | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 474 | Christine Peschken | Epidemiology of ANCA-Associated Vasculitis (AAV) in a Multiethnic Tertiary Care Centre Cohort | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 475 | Tatiana Reshetnyak | Citrullinated histone H3 (CitH3) in ANCA-associated vasculitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 476 | Takuya Saito | Clinical characteristics of patients with giant cell arteritis achieving glucocorticoid-free remission with tocilizumab and real-world patterns of tocilizumab dose spacing | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 477 | Jed Salazar | Beyond the Wheal: A Rare Case of Normocomplementemic Urticarial Vasculitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 478 | Zomuan Sanga | Exceedingly Rare Coexistence of Biopsy-Proven Vasculitic Neuropathy and Inflammatory Myositis as Initial Presentation of SLE with Secondary Sjögren’s Syndrome Overlap | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 479 | Muhammad Ibrahim Shahzad | Weight Gain In Year 1 Following Diagnosis With Large Vessel Vasculitis | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 480 | Aman Sharma | Etiology, Risk Factors, and Short-term Outcomes of Peripheral Gangrene: A Prospective Observational Study from a Tertiary Care Center | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 481 | Mayu Shiomi | Distinct longitudinal MPO-ANCA titer trajectories are differentially associated with relapse and survival in microscopic polyangiitis: the multicenter REVEAL cohort study | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 482 | Yin Minn Soe | Starting AAV journey with the eyes | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 483 | Hiromichi Tamaki | Real-world Efficacy of Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Comparison Based on the Five-Factor Score | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 484 | Nicole Tan | Rituximab-Induced Dual Cytopenia in MPO-ANCA Vasculitis: A Rare Case from Singapore | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 485 | Rose Vita Sari | Spectrum of Life-Threatening Vascular Manifestations in Takayasu Arteritis: A Case Series | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 486 | Kiran Wakade | Takayasu Arteritis Presenting as Dilated Cardiomyopathy: A Retrospective Observational Cohort from a Tertiary Care Centre in India | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 487 | Hong Wei-jhe | Rupture of aneurysm in right middle cerebral artery related to Takayasu arteritis in a 46 y/o female patient | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 488 | Sabrina Yesmin | An Unusual Case of Takayasu Arteritis Masquerading as Coarctation of Aorta | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 489 | Sabrina Yesmin | Fulminant Postpartum Polyarteritis Nodosa Presenting with Extensive Cutaneous Necrosis and Symmetrical Peripheral Gangrene Leading to Sudden Death | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 490 | Anel Zhumabek | Management of Refractory Steroid-Dependent Eosinophilic Granulomatosis with Polyangiitis with Multisystem Involvement | 3 | F |
| Systemic vasculitis related to rheumatic diseases | 491 | Anel Zhumabek | PR3-ANCA-Positive Granulomatosis with Polyangiitis Mimicking Pulmonary Infection | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications | 492 | Qian Guo | Application of IFI44L Gene Methylation Levels in the Diagnosis and Disease Assessment of Connective Tissue Diseases | 3 | F |
| Autoinflammatory diseases | 493 | Aditya Melti | Autoimmune Hepatitis–Primary Sclerosing Cholangitis Overlap: A Diagnostic Challenge in Autoimmune Liver Disease Spectrum | 3 | F |
| Antiphospholipid syndrome | 494 | Dewi Mustikarani | Multiple Arterial and Venous Thrombosis with Lupus Anticoagulant Positivity in Severe Infection: A Diagnostic Challenge of Probable Catastrophic Antiphospholipid Syndrome | 3 | F |
Posters will be displayed across three designated areas:
Poster Area 1:
Gallery A & Gallery B, Exhibition Hall (Level 1)
Poster Area 2:
Gallery C, Gallery D & Gallery E, Auditorium Foyer (Level 3)
Poster Area 3:
Gallery F, E-Room Foyer (Level 3)
